For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Nektar Therapeutics (NASDAQ: NKTR) was $0.66 for the day, up 6.09% from the previous closing price of $0.63. In other words, the price has increased by $6.09 from its previous closing price. On the day, 1.07 million shares were traded. NKTR stock price reached its highest trading level at $0.6694 during the session, while it also had its lowest trading level at $0.6254.
Ratios:
Our analysis of NKTR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.26 and its Current Ratio is at 4.26. In the meantime, Its Debt-to-Equity ratio is 3.20 whereas as Long-Term Debt/Eq ratio is at 2.87.
On March 14, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $6.
On January 08, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on January 08, 2025, with a $4 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 19 ’25 when Zalevsky Jonathan sold 10,300 shares for $1.01 per share. The transaction valued at 10,403 led to the insider holds 316,604 shares of the business.
Wilson Mark Andrew sold 11,040 shares of NKTR for $11,150 on Feb 19 ’25. The Chief Legal Officer now owns 324,292 shares after completing the transaction at $1.01 per share. On Feb 19 ’25, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 23,774 shares for $1.01 each. As a result, the insider received 24,012 and left with 1,086,901 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 123573048 and an Enterprise Value of 62686784. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.26 while its Price-to-Book (P/B) ratio in mrq is 2.03. Its current Enterprise Value per Revenue stands at 0.637 whereas that against EBITDA is -0.499.
Stock Price History:
The Beta on a monthly basis for NKTR is 0.65, which has changed by -0.5217391 over the last 52 weeks, in comparison to a change of 0.042615533 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.43. The 50-Day Moving Average of the stock is -13.53%, while the 200-Day Moving Average is calculated to be -37.94%.
Shares Statistics:
NKTR traded an average of 2.41M shares per day over the past three months and 2769830 shares per day over the past ten days. A total of 185.78M shares are outstanding, with a floating share count of 179.37M. Insiders hold about 3.62% of the company’s shares, while institutions hold 69.45% stake in the company. Shares short for NKTR as of 1743379200 were 7770464 with a Short Ratio of 3.23, compared to 1740700800 on 6624341. Therefore, it implies a Short% of Shares Outstanding of 7770464 and a Short% of Float of 5.3200003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 3.0 analysts currently analyzing and rating the stock of Nektar Therapeutics (NKTR).The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.17 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.61 and -$0.79 for the fiscal current year, implying an average EPS of -$0.72. EPS for the following year is -$0.76, with 3.0 analysts recommending between -$0.67 and -$0.87.
Revenue Estimates
Based on 8 analysts’ estimates, the company’s revenue will be $63.11M in the next fiscal year. The high estimate is $132.74M and the low estimate is $24M.
